[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369121-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369121-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","a-novel-oncolytic-vaccinia-virus-armed-with-il-12-augments-antitumor-immune-responses-leading-to-durable-regression-in-murine-models-of-lung-cancer","A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer","","Oncolytic vaccinia viruses were evaluated as immune-stimulating treatments for solid tumors, focusing on a genetically modified IL-12–armed variant (VVL-m12) as therapy for murine lung cancer models. Cytotoxicity and viral replication were tested in lung cancer cell lines, followed by intratumoral delivery in immunocompetent mouse models. VVL-m12 showed superior antitumor activity and synergized with PD-1 blockade or soluble PD-1, increasing effector and central memory T-cell responses, enhancing dendritic cell activation, shifting macrophages toward an M1 phenotype, inhibiting angiogenesis, and enabling safe durable tumor clearance without recurrence.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/a-novel-oncolytic-vaccinia-virus-armed-with-il-12-augments-antitumor-immune-responses-leading-to-durable-regression-in-murine-models-of-lung-cancer/369121/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/a-novel-oncolytic-vaccinia-virus-armed-with-il-12-augments-antitumor-immune-responses-leading-to-durable-regression-in-murine-models-of-lung-cancer/369121.png","ImageObject",300,407,{"name":42,"@type":43},"Finn","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is VVL-m12 and what therapeutic role does it play in the study?","Question",{"text":63,"@type":64},"VVL-m12 is a next-generation genetically modified vaccinia virus armed with interleukin-12 (IL-12). The study tests it as a therapeutic strategy to treat murine lung cancer models and to increase sensitivity to PD-1–based antibody therapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were the antitumor effects of the viruses assessed?",{"text":68,"@type":64},"The cytotoxicity and replication of VVL-m12, VVL-h12, and control viruses were evaluated in lung cancer cell lines. Subcutaneous lung cancer mouse models were then used to examine antitumor activity after intratumoral delivery.",{"name":70,"@type":61,"acceptedAnswer":71},"What combination approaches were investigated and what outcomes were observed?",{"text":72,"@type":64},"The study tested synergy between VVL-m12 and PD-1 blockade (a-PD1), as well as pairing with a VV armed with soluble PD-1 (VV-sPD1). Rational combination significantly enhanced survival and safely cured lung cancer without evidence of recurrence.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369121,1790465597,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":108,"preview_page_count":33,"preview_urls":145},34359740700684,"https://ap-avatar.wpscdn.com/avatar/1f400023980c374ae676?_k=1777273430885731487","TYPE Original Research PUBLISHED 07 January 2025  \nDOI 10.3389/fimmu.2024.1492464  \nOPEN ACCESS  \nEDITED BY  \nIngo Drexler,  \nHeinrich-Heine-University, Germany  \nREVIEWED BY  \nShuguang Zuo,  \nAfﬁliated Liutie Central Hospital of Guangxi Medical University, China  \nPriscilla S. Briquez,  \nUniversity of Freiburg Medical Center, Germany  \n*CORRESPONDENCE  \nYaohe Wang  \n[yaohe.wang@qmul.ac.uk](yaohe.wang@qmul.ac.uk)  \nRECEIVED 07 September 2024  \nACCEPTED 10 December 2024  \nPUBLISHED 07 January 2025  \nCORRECTED 04 March 2026  \nCITATION  \nChen L, Wang P, Di Gioia C, Yuan M, Zhang Z, Miao J, Yan W, Zhao G, Jia Y, Wang N, Zhang Z, Guo H, Marelli G, Dunmall LC, Lemoine NR and Wang Y (2025) A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer.  \nFront. Immunol. 15:1492464 .  \ndoi: 10.3389/fimmu.2024.1492464  \nCOPYRIGHT  \n© 2025 Chen, Wang, Di Gioia, Yuan, Zhang, Miao, Yan, Zhao, Jia, Wang, Zhang, Guo, Marelli, Dunmall, Lemoine and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nA novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer  \nLijuan Chen 1,2, Pengju Wang 3, Carmela Di Gioia 4, Ming Yuan 4, Zhe Zhang 3, Jinxin Miao 3, Wenli Yan 3, Guanghao Zhao 3, Yangyang Jia 3, Na Wang 3, Zhongxian Zhang 3, Haoran Guo 3, Giulia Marelli 4, Louisa Chard Dunmall 4, Nicholas R. Lemoine 3,4 and Yaohe Wang 3,4*  \n1 Department of Oncology, the Afﬁliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China, 2 Henan International Joint Laboratory of Lung Cancer Biology and Therapeutics, Zhengzhou, China, 3Sino-British Research Centre for Molecular Oncology, National Centre for International Research in Cell and Gene Therapy, School of Basic Medical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China, 4Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom  \nOncolytic vaccinia viruses (VVs) are potent stimulators of the immune system and induce immune-mediated tumor clearance and long-term surveillance against tumor recurrence. As such they are ideal treatment modalities for solid tumors including lung cancer. Here, we investigated the use of VVL-m12, a nextgeneration, genetically modiﬁed, interleukin-12 (IL-12)-armed VV, as a new therapeutic strategy to treat murine models of lung cancer and as a mechanism of increasing lung cancer sensitivity to antibody against programmed cell death protein 1 (a-PD1) therapy. The cytotoxicity and replication of VVL-m12, VVL-h12 and control VVs were assessed in lung cancer cell lines. Subcutaneous lung cancer mouse models were established to investigate the anti-tumor activity of the viruses after intratumoral delivery inan immunocompetent disease model. Synergy with a-PD1 or a VV armed with soluble PD-1 (VV-sPD1) was investigated and functional mechanisms behind efﬁcacy probed. Tumor-targeted VVL-m12 replicated to high levels, was cytotoxic in lung cancer cell lines. VVL-m12 demonstrated superior antitumor efﬁcacy in subcutaneous lung cancer models compared with other VVs examined. Importantly, rational combination of VVL-m12 and PD-1 blockade worked synergistically to signiﬁcantly enhance survival of animals and safely cured lung cancer with no evidence of recurrence. VVL-m12 therapy induced increased intratumoral inﬁltration of CD4+ and CD8+ T cells and was able to clear tumor at early time points vi","cbCaiciTPQQ3grrg","https://ap.wps.com/l/cbCaiciTPQQ3grrg","pdf",4925634,16,"English","# Abstract / Overview\n## Study rationale\n## Experimental design (cell and mouse models)\n## Combination strategies (PD-1 blockade, soluble PD-1)\n## Immunological and tumor microenvironment mechanisms\n## Key findings and implications","[{\"question\":\"What is VVL-m12 and what therapeutic role does it play in the study?\",\"answer\":\"VVL-m12 is a next-generation genetically modified vaccinia virus armed with interleukin-12 (IL-12). The study tests it as a therapeutic strategy to treat murine lung cancer models and to increase sensitivity to PD-1–based antibody therapy.\"},{\"question\":\"How were the antitumor effects of the viruses assessed?\",\"answer\":\"The cytotoxicity and replication of VVL-m12, VVL-h12, and control viruses were evaluated in lung cancer cell lines. Subcutaneous lung cancer mouse models were then used to examine antitumor activity after intratumoral delivery.\"},{\"question\":\"What combination approaches were investigated and what outcomes were observed?\",\"answer\":\"The study tested synergy between VVL-m12 and PD-1 blockade (a-PD1), as well as pairing with a VV armed with soluble PD-1 (VV-sPD1). Rational combination significantly enhanced survival and safely cured lung cancer without evidence of recurrence.\"}]","A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer | PDF",1790180860,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7337ea3ef4843d9d187f1bd5f224fc0e.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca5f135d1ffe69911e43b834bc989016.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b4f769d7f0d0380595e0ced83dbf66d.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1191bd4574af35e2da834fa65c101c9e.webp",980,1385]